Bernstein sees TI’s likely price hike benefiting Infineon, Renesas stock
David E.I. Pyott, a director at Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), recently executed a significant stock transaction. The $36.4 billion biotech company, which has delivered an impressive 91% return over the past year according to InvestingPro data, saw Pyott sell 7,440 shares of common stock on March 24, 2025, at $299 per share, totaling approximately $2.2 million.
This transaction was part of a pre-established Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stocks to avoid potential accusations of insider trading. The options exercised by Pyott were set to expire on December 18, 2025. The company maintains a strong financial position with a healthy current ratio of 2.78 and has demonstrated robust revenue growth of 23% in the last twelve months.
In addition to the sale, Pyott also exercised options to acquire 7,440 shares at a price of $88.95 per share, resulting in a total transaction value of approximately $661,788. Following these transactions, Pyott holds 136 shares directly and 27,900 shares indirectly through a trust. For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro subscribers can access detailed financial health scores and 12 additional ProTips about Alnylam’s performance and outlook.
In other recent news, Alnylam Pharmaceuticals has received significant attention following the FDA approval of its drug Amvuttra for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). This approval has been highlighted by several analysts, including RBC Capital, H.C. Wainwright, JPMorgan, Stifel, and Scotiabank (TSX:BNS), who have all maintained or raised their price targets for the company. RBC Capital continues to hold a target of $330, while H.C. Wainwright has set a target of $500, citing Amvuttra’s potential to become a dominant therapy due to its promising clinical results. JPMorgan upgraded Alnylam’s stock rating to Overweight, increasing the price target to $328, reflecting optimism about the company’s market potential. Stifel maintains a $300 target, emphasizing the strategic pricing and labeling of Amvuttra, which includes mortality data that differentiates it from competitors. Scotiabank raised its price target to $338, noting the drug’s groundbreaking nature as the first transthyretin silencer available for this condition. Analysts have pointed out the strong market opportunity for Amvuttra, with its favorable pricing strategy expected to support high patient compliance. These developments are seen as key drivers for Alnylam’s growth and market presence in the ATTR amyloidosis treatment sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.